PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 21(1): 14-24 2001
© 2001 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Navarro, J.
Right arrow Articles by Mora, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Navarro, J.
Right arrow Articles by Mora, C
Peritoneal Dialysis International, Vol 21, Issue 1, 14-24
Copyright © 2001 by International Society for Peritoneal Dialysis

Articles

In-depth review effect of androgens on anemia and malnutrition in renal failure: implications for patients on peritoneal dialysis

JF Navarro and C Mora

Nephrology Service and Research Unit, Hospital Nuestra Senora de Candelaria, Santa Cruz de Tenerife, Spain. jnavarro@hcan.rcanaria.es

OBJECTIVE: To analyze the implications of the potential use of androgens in peritoneal dialysis patients, focusing on their effects on hematologic and nutritional parameters.This manuscript reviews the different compounds for clinical use, dosage schedules, adverse effects, and how therapy with androgens might be used to treat anemia and malnutrition in these dialysis patients. DATA SOURCES: Studies in the literature dealing with the effects of androgens on hematologic and nutritional parameters, and their role in uremic anemia and malnutrition. STUDY SELECTION: Studies in which uremic patients received androgens as therapy for anemia or malnutrition. DATA EXTRACTION: Data were abstracted from all of these studies. RESULTS: This review shows that androgens are anabolic substances that also have significant actions on erythropoiesis. A number of clinical studies in uremic patients have found that these compounds have beneficial effects on hematologic parameters and nutritional status, similarly to other therapies, such as recombinant human erythropoietin and recombinant human growth hormone, respectively. CONCLUSIONS: Androgens have been shown to have a beneficial effect on anemia due to renal disease and on nutritional status in uremic patients. Further studies need to be done with larger groups of patients. Objectives for additional research are suggested.




This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
B. Feldt-Rasmussen, M. Lange, W. Sulowicz, U. Gafter, K. N. Lai, J. Wiedemann, J. S. Christiansen, M. El Nahas, and and the Adult Patients in Chronic Dialysis (APCD)
Growth Hormone Treatment during Hemodialysis in a Randomized Trial Improves Nutrition, Quality of Life, and Cardiovascular Risk
J. Am. Soc. Nephrol., July 1, 2007; 18(7): 2161 - 2171.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. F. Navarro
In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example
Nephrol. Dial. Transplant., November 1, 2003; 18(11): 2222 - 2226.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2001 by Multimed Inc.